000148414 001__ 148414
000148414 005__ 20240229112703.0
000148414 0247_ $$2doi$$a10.1016/j.trecan.2019.10.002
000148414 0247_ $$2pmid$$apmid:31813451
000148414 0247_ $$2ISSN$$a2405-8025
000148414 0247_ $$2ISSN$$a2405-8033
000148414 0247_ $$2altmetric$$aaltmetric:69533236
000148414 037__ $$aDKFZ-2019-02969
000148414 041__ $$aeng
000148414 082__ $$a610
000148414 1001_ $$0P:(DE-He78)34b3639de467b2c700920d7cbc3d2110$$aOkonechnikov, Konstantin$$b0$$eFirst author$$udkfz
000148414 245__ $$aProbing Medulloblastoma Initiation at the Single-Cell Level.
000148414 260__ $$aAmsterdam$$bElsevier$$c2019
000148414 3367_ $$2DRIVER$$aarticle
000148414 3367_ $$2DataCite$$aOutput Types/Journal article
000148414 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1577975187_14125$$xEditorial
000148414 3367_ $$2BibTeX$$aARTICLE
000148414 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000148414 3367_ $$00$$2EndNote$$aJournal Article
000148414 500__ $$aEA:B062LA:B062Editorial MaterialSpotlight
000148414 520__ $$aMedulloblastoma is a pediatric brain tumor arising from the developing cerebellum. Despite significant strides in classifying tumor subgroups and identifying underlying genetic mutations, progress in clinical outcomes has been notably slower. About 30% of patients experience relapse after treatment, possibly because of our inability to identify and eliminate the cancer stem cells. Zhang et al. recently investigated these cells in the SHH subgroup of medulloblastoma and identified drugs that may target them.
000148414 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000148414 588__ $$aDataset connected to CrossRef, PubMed,
000148414 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan M$$b1$$udkfz
000148414 7001_ $$0P:(DE-He78)a56d7a8e916d458441b5ac9484d73c5d$$aKutscher, Lena$$b2$$eLast author$$udkfz
000148414 773__ $$0PERI:(DE-600)2852626-0$$a10.1016/j.trecan.2019.10.002$$gVol. 5, no. 12, p. 759 - 761$$n12$$p759 - 761$$tTrends in cancer$$v5$$x2405-8033$$y2019
000148414 909CO $$ooai:inrepo02.dkfz.de:148414$$pVDB
000148414 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)34b3639de467b2c700920d7cbc3d2110$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000148414 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000148414 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a56d7a8e916d458441b5ac9484d73c5d$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000148414 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000148414 9141_ $$y2019
000148414 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000148414 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000148414 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000148414 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000148414 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000148414 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000148414 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000148414 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x1
000148414 980__ $$ajournal
000148414 980__ $$aVDB
000148414 980__ $$aI:(DE-He78)B062-20160331
000148414 980__ $$aI:(DE-He78)L101-20160331
000148414 980__ $$aUNRESTRICTED